Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924

Cancer Research

Volumn 73, Issue 1, 2013, Pages 225-234

  Blank, Jonathan L ^a   Liu, Xiaozhen J ^a   Cosmopoulos, Katherine ^a   Bouck, David C ^a   Garcia, Khristofer ^a   Bernard, Hugues ^a   Tayber, Olga ^a   Hather, Greg ^a   Liu, Ray ^a   Narayanan, Usha ^a   Milhollen, Michael A ^a   Lightcap, Eric S ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; ATR PROTEIN; NEDD8 PROTEIN; PROTEIN P21; REPLICATION LICENSING FACTOR CDT1; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE CHECKPOINT; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; EXCISION REPAIR; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE IDENTIFICATION; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MELANOMA CELL; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLOPENTANES; DNA DAMAGE; FLOW CYTOMETRY; HUMANS; MELANOMA; POLYMERASE CHAIN REACTION; PYRIMIDINES; UBIQUITINS;

EID: 84871962551     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1729     Document Type: Article

References (53)

1. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
2. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010;116:1515-23.
3. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010;115:3796-800.
4. Wang M, Medeiros BC, Erba HP, DeAngelo DJ, Giles FJ, Swords RT. Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin Ther Targets 2011;15:253-64.
5. Huang DT, Ayrault O, Hunt HW, Taherbhoy AM, Duda DM, Scott DC, et al. E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell 2009;33:483-95.
6. Tanaka T, Nakatani T, Kamitani T. Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy. Mol Oncol 2012;6:267-75.
7. Sarikas A, Hartmann T, Pan ZQ. The cullin protein family. Genome Biol 2011;12:220.
8. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010;1:708-16.
9. Li JM, Jin J. CRL ubiquitin ligases and DNA damage response. Front Oncol 2012;2:29.
10. Wu J, Zhang X, Zhang L, Wu CY, Rezaeian AH, Chan CH, et al. Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol Cell 2012;46:351-61.
11. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010;70:10310-20.
12. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011;71:3042-51.
13. Truong LN, Wu X. Prevention of DNA re-replication in eukaryotic cells. J Mol Cell Biol 2011;3:13-22.
14. Blow JJ, Gillespie PJ. Replication licensing and cancer-a fatal entanglement? Nat Rev Cancer 2008;8:799-806.
15. Hook SS, Lin JJ, Dutta A. Mechanisms to control rereplication and implications for cancer. Curr Opin Cell Biol 2007;19:663-71.
16. Arias EE, Walter JC. Strength in numbers: preventing rereplication via multiple mechanisms in eukaryotic cells. Genes Dev 2007;21:497-518.
17. Blow JJ, Dutta A. Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol 2005;6:476-86.
18. Nishitani H, Sugimoto N, Roukos V, Nakanishi Y, Saijo M, Obuse C, et al. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J 2006;25:1126-36.
19. Jin J, Arias EE, Chen J, Harper JW, Walter JC. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 2006;23:709-21.
20. Senga T, Sivaprasad U, Zhu W, Park JH, Arias EE, Walter JC, et al. PCNA is a cofactor for Cdt1 degradation by CUL4/DDB1-mediated N-terminal ubiquitination. J Biol Chem 2006;281:6246-52.
21. Sansam CL, Shepard JL, Lai K, Ianari A, Danielian PS, Amsterdam A, et al. DTL/CDT2 is essential for both CDT1 regulation and the early G2/M checkpoint. Genes Dev 2006;20:3117-29.
22. Liu E, Lee AY, Chiba T, Olson E, Sun P, Wu X. The ATR-mediated S phase checkpoint prevents rereplication in mammalian cells when licensing control is disrupted. J Cell Biol 2007;179:643-57.
23. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 2003;11:997-1008.
24. Hannah J, Zhou P. Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases. DNA Repair (Amst) 2009;8:536-43.
25. Hannß R, Dubiel W. COP9 signalosome function in the DDR. FEBS Lett 2011;585:2845-52.
26. Abbas T, Dutta A. CRL4Cdt2: master coordinator of cell cycle progression and genome stability. Cell Cycle 2011;10:241-9.
27. Kee Y, Kim JM, D'Andrea AD. Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Genes Dev 2009;23:555-60.
28. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007;6:556-68.
29. Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 2011;117:6074-82.
30. Boehm JS, Hahn WC. Towards systematic functional characterization of cancer genomes. Nat Rev Genet 2011;12:487-98.
31. Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 2010;70:4318-26.
32. Svendsen JM, Smogorzewska A, Sowa ME, O'Connell BC, Gygi SP, Elledge SJ, et al. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required forDNArepair. Cell 2009;138:63-77.
33. Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K, et al. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics 2011;10:M111.009183.
34. Flynn RL, Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci 2011;36:133-40.
35. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16:376-83.
36. Hanawalt PC, Spivak G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat Rev Mol Cell Biol 2008;9:958-70.
37. Jain AK, Barton MC. Making sense of ubiquitin ligases that regulate p53. Cancer Biol Ther 2010;10:665-72.
38. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 2011;13:561-9.
39. Yang D, Tan M, Wang G, Sun Y. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS ONE 2012;7:e34079.
40. Zhu W, Dutta A. An ATR- and BRCA1-mediated Fanconi anemia pathway is required for activating the G2/M checkpoint and DNA damage repair upon rereplication. Mol Cell Biol 2006;26:4601-11.
41. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010;11:138-48.
42. Garner KM, Eastman A. Variations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in the cell lines of the NCI60 panel. BMC Cancer 2011;11:206:1-13.
43. Brown KD, Rathi A, Kamath R, Beardsley DI, Zhan Q, Mannino JL, et al. The mismatch repair system is required for S-phase checkpoint activation. Nat Genet 2003;33:80-4.
44. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 2002;3:248-54.
45. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
46. Ochocka AM, Kampanis P, Nicol S, Allende-Vega N, Cox M, Marcar L, et al. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett 2009;583:621-6.
47. Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, et al. KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem 2006;281:14711-8.
48. Lee SJ, Lim CJ, Min JK, Lee JK, Kim YM, Lee JY, et al. Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2. Cell Death Differ 2007;14:1106-16.
49. Abe Y, Takeuchi T, Imai Y, Murase R, Kamei Y, Fujibuchi T, et al. A Small Ras-like protein Ray/Rab1c modulates the p53-regulating activity of PRPK. Biochem Biophys Res Commun 2006;344:377-85.
50. Shu L, Yan W, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript. Genes Dev 2006;20:2961-72.
51. Kee Y, Huang M, Chang S, Moreau L, Park E, Smith PG, et al. Inhibition of the Nedd8 system sensitizes cells to DNA Interstrand crosslinking agents. Mol Cancer Res 2012;10:369-77.
52. Zhu Y, Alvarez C, Doll R, Kurata H, Schebye XM, Parry D, et al. Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol Cell Biol 2004;24:6268-77.
53. Kan Q, Jinno S, Kobayashi K, Yamamoto H, Okayama H. Cdc6 determines utilization of p21(WAF1/CIP1)-dependent damage checkpoint in S phase cells. J Biol Chem 2008;283:17864-72.